Caris Life Sciences Announces Presentations at 2018 SGO Annual Meeting on Women's Cancer Highlighting Tumor Profiling for Immunotherapy Advances

Presentations demonstrate utility of tumor profiling to guide individualized treatment

Relationship between immunotherapy associated biomarkers, MSI, TMB and PD-L1, explored across more than 5,000 gynecologic cancer cases

News provided by

Caris Life Sciences

Mar 22, 2018, 06:30 ET

IRVING, Texas, March 22, 2018 /PRNewswire/ -- Caris Life Sciences^®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of four abstracts, including two featured poster presentations, for presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held March 24–27, 2018, in New Orleans, LA. The studies were conducted in collaboration with industry-leading academic and clinical institutions employing the company's proprietary Caris Molecular Intelligence^®Comprehensive Genomic Profiling Plus (CGP+) tumor profiling platform that assesses DNA, RNA and proteins to aid clinicians in delivering the most optimal and personalized treatment plan for each patient.

"The success of immunotherapies is opening a new era in the treatment of gynecologic tumors. Caris is leading the way in identifying patients more likely to respond to these drugs with our PD-L1, MSI and TMB testing," said W. Michael Korn, M.D., Chief Medical Officer of Caris Life Sciences. "We are excited to be a part of the annual SGO meeting where we can share our experience with these important biomarkers across several gynecologic cancer types."

Featured Poster Sessions:

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer
(Abstract #84)
Sunday, March 25, 3:45 – 4:45 p.m. CT
Elite Hall AB
Authors: N.L. Jones, J. Xiu, T. Herzog, I. Winer.
Institutions: University of South Alabama Mitchell Cancer Institute, Caris Life Sciences, UC Health Barrett Cancer Center, Wayne State University

Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy
(Abstract #85)
Sunday, March 25, 3:45 – 4:45 p.m. CT
Elite Hall AB
Authors: I. Winer, N.L. Jones, J. Xiu, A. Ellerbrock, J. Brown, T. Herzog.
Institutions: Wayne State University, University of South Alabama Mitchell Cancer Institute, Caris Life Sciences, Levine Cancer Institute, Carolinas Medical Center, UC Health Barrett Cancer Center

Poster Sessions:

Distinct molecular profiles and potential therapeutic targets in androgen receptor stratified ovarian cancer patients
(Poster #395)
Sunday, March 25, 3:30 – 4:30 p.m. CT
Empire A
Authors: N.L. Jones, J. Xiu, J.M. Scalici, M.A. Finan, I. Winer, J. Young Pierce, R.P. Rocconi. Institutions: University of South Alabama Mitchell Cancer Institute, Caris Life Sciences, Wayne State University

Molecular variation in uterine carcinosarcoma: Are there therapeutic opportunities?
(Poster #391)
Sunday, March 25, 3:30 – 4:30 p.m. CT
Empire A
Authors: E.K. Crane, K. Poorman, R.W. Naumann, D.L. Tait, R.V. Higgins, J. Brown,T. Herzog. Institutions: Levine Cancer Institute, Carolinas Medical Center, Caris Life Sciences, UC Health Barrett Cancer Center

About Caris Life Sciences^®Caris Life Sciences^® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation, and the world's leading immunotherapy diagnostic expert. Caris Molecular Intelligence^®, the company's Comprehensive Genomic Profiling Plus (CGP+) molecular testing service, assesses DNA, RNA and proteins, including microsatellite instability (MSI), tumor mutational burden (TMB) and PD-L1, to reveal a molecular blueprint to guide more precise and personalized treatment decisions. The ADAPT Biotargeting System^™, the company's revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
[email protected] / [email protected]
Tel: +1-508-280-6592 / +1-646-536-7006

SOURCE Caris Life Sciences